19 Jul 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Complete Genomics, a wholly-owned subsidiary of China-based BGI-Shenzhen, entered into a settlement agreement with Illumina, under which the later will dismiss with prejudice both lawsuits it had brought against Complete.
The two law suits include Illumina and Solexa vs Complete Genomics; Case No. 10-cv-05542 EDL (N.D. Cal.); and Illumina and Illumina Cambridge vs Complete Genomics; Case No. 12-cv-01465 BEN BGS (S.D. Cal).
Complete will dismiss with prejudice all counterclaims. The parties have entered into mutual releases, and each party will bear its own litigation costs. No payment is being made by either party to the other, and no licenses are being granted by either party to the other.
Dr Clifford Reid, CEO, Complete Genomics, said that, "We are pleased to have reached a settlement with Illumina regarding this matter. This resolution allows Complete to focus on its vision of revolutionizing medicine through the use of whole genome sequencing."